预约演示
更新于：2025-04-25
Amlodipine besilate/Valsartan
苯磺酸氨氯地平/缬沙坦
更新于：2025-04-25
概要
基本信息
药物类型 小分子化药 |
别名 Amlodipine (as besylate)/Valsartan、Amlodipine /Valsartan、Amlodipine/Valsartan + [16] |
作用方式 拮抗剂、阻滞剂 |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2007-01-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS号137862-53-4 |
查看全部结构式(2)
关联
109
项与 苯磺酸氨氯地平/缬沙坦 相关的临床试验NCT06625346
Clinical Outcomes in Newly Diagnosed Hypertensive Patients with EXTOR (Fixed-Dose Combination of Amlodipine/Valsartan) in Routine Pakistani Practice.
CTR20242402
缬沙坦氨氯地平片（I）在健康人体空腹/餐后状态下的
生物等效性试验
NCT06193044
A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Amlodipine and Valsartan Tablets 10/160 mg and Reference Product (Exforge® 10/160 mg Tablets)
100 项与 苯磺酸氨氯地平/缬沙坦 相关的临床结果
登录后查看更多信息
100 项与 苯磺酸氨氯地平/缬沙坦 相关的转化医学
登录后查看更多信息
100 项与 苯磺酸氨氯地平/缬沙坦 相关的专利（医药）
登录后查看更多信息
17
项与 苯磺酸氨氯地平/缬沙坦 相关的文献（医药）2024-07-01BioFactors (Oxford, England)
Sacubitril/valsartan promotes white adipose tissue browning in rats with metabolic syndrome through activation of mTORC1
Article
作者: Novakovic, Jovana ; Lazarevic, Nevena ; Jeremic, Nevena ; Nedeljkovic, Nikola ; Nikolic, Marina ; Nikolic, Milos ; Mitrovic, Slobodanka ; Zivkovic, Vladimir ; Jakovljevic, Vladimir ; Stojanovic, Aleksandra ; Milojevic Samanovic, Andjela
Abstract:
In addition to their usual use in the treatment of cardiovascular disease, weak evidence is available for the potential of combined use of neprilysin inhibitor (sacubitril) and AT1 receptor antagonist (valsartan) to promote browning of white adipose tissue (WAT) in rats with metabolic syndrome (MetS). This study involved 32 male Wistar albino rats divided into four groups: CTRL—healthy control rats; ENT—healthy rats treated with sacubitril/valsartan; MS—rats with MetS; MS + ENT—rats with MetS treated with sacubitril/valsartan. After finishing the experimental protocol, different WAT depots were isolated for further analysis of molecular pathways. Molecular docking and molecular dynamics studies were used for in silico assessment of the binding affinity of sacubitril and valsartan towards subunits of mechanistic target of rapamycin complex 1 (mTORC1). Sacubitril/valsartan treatment markedly diminished morphological changes in adipose tissue, resulting in smaller lipid size and multilocular lipid droplet structure in WAT. We showed significantly higher protein expression of uncoupling protein‐1 (UCP‐1) and mTORC1 in WAT of MS + ENT rats, correlating with increased relative gene expression of browning‐related markers in tissue of rats treated with sacubitril/valsartan compared with MS group of rats. In silico analysis showed that sacubitrilat and valsartan exhibited the highest binding affinity against mTOR and mLST8, forming stable complexes with these mTORC1 subunits. The observed results confirmed strong potential of combined sacubitril/valsartan treatment to increase browning markers expression in different WAT depots in MetS condition and to form permanent complexes with mTOR and mLST8 subunits over the time.
2022-10-04Journal of the American Heart Association
Global Longitudinal Strain and Biomarkers of Cardiac Damage and Stress as Predictors of Outcomes After Transcatheter Aortic Valve Implantation
Article
作者: Patel, Jay N. ; Vatterott, Anna ; Gupta, Deepak K. ; Kumbhani, Dharam J. ; Baker, Michael ; Mallugari, Ravinder R. ; Clark, Daniel E. ; Jackson, Natalie ; Gillam, Linda ; Gonzales, Holly ; Fearon, William F. ; Lindman, Brian R. ; Kapadia, Samir ; Piana, Robert N. ; Kim, Juyong B. ; Zajarias, Alan ; Perry, Andrew S. ; Biersmith, Michael ; Quader, Nishath ; Stein, Elliot J. ; Bavry, Anthony A. ; Elmariah, Sammy ; Whisenant, Brian ; Coylewright, Megan ; Huang, Shi ; Welt, Frederick G.
Background:
Global longitudinal strain (GLS) is a sensitive measure of left ventricular function and a risk marker in severe aortic stenosis. We sought to determine whether biomarkers of cardiac damage (cardiac troponin) and stress (NT‐proBNP [N‐terminal pro‐B‐type natriuretic peptide]) could complement GLS to identify patients with severe aortic stenosis at highest risk.
Methods and Results:
From a multicenter prospective cohort of patients with symptomatic severe aortic stenosis who underwent transcatheter aortic valve implantation, we measured absolute GLS (aGLS), cardiac troponin, and NT‐proBNP at baseline in 499 patients. Left ventricular ejection fraction <50% was observed in 19% and impaired GLS (aGLS <15%) in 38%. Elevations in cardiac troponin and NT‐proBNP were present in 79% and 89% of those with impaired GLS, respectively, as compared with 63% and 60% of those with normal GLS, respectively (
P
<0.001 for each). aGLS <15% was associated with increased mortality in univariable analysis (
P
=0.009), but, in a model with both biomarkers, aGLS, and clinical covariates included, aGLS was not associated with mortality; elevation in each biomarker was associated with an increased hazard of mortality (adjusted hazard ratio, >2;
P
≤0.002 for each) when the other biomarker was elevated, but not when the other biomarker was normal (interaction
P
=0.015).
Conclusions:
Among patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve implantation, elevations in circulating cardiac troponin and NT‐proBNP are more common as GLS worsens. Biomarkers of cardiac damage and stress are independently associated with mortality after transcatheter aortic valve implantation, whereas GLS is not. These findings may have implications for risk stratification of asymptomatic patients to determine optimal timing of valve replacement.
2018-09-01Georgian medical news
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Article
作者: Gegeshidze, N ; Tabukashvili, R ; Tchaava, K ; Kapetivadze, V ; Maglapheridze, Z ; Lazashvili, T
Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia. Were studied 58 patients (40-65 years old) with hypertension (the level of arterial pressure was ≥140/90 and ≤180/110mm.Hg.RR). The patients have been divided into 3 groups: Group 1( n=18, middle age 55,8±5,9) were given Amlodipin 10 mg., Fenofibrates 200mg. (Lipantil); Group 2 (n=20, middle age 58,0±4,9) were given Exforge (Amlodipin 5mg./Valsartan 160mg.) and Lipantil 200mg.; Group3 (n=20, middle age 57,0±6,9) were given Exforge. Research duration- 4 months. Was done collection of anamnesis, calculation of BMI, Heart rate, Blood pressure. Before and after observation were investigated: lipid range, Total Cholesterol, Triglycerides, High Density Lipoproteins, Low Density Lipoproteins by using W.Friedwald's formula. After 4 month in group 3 was found significantly reduce of Blood Pressure, systolic- 26,6%, (р<0,001), and diastolic - 18,0%; Significantly improve Lipid range. Were decreased the levels of Total Cholesterol -14,5%, Triglycerides-15,9%, Low Density Lipoproteins -20,2%. The combined therapy by Exforge and fibrates provides effective decrease in levels of blood pressure and improvement in lipid range in hypertensive patients with dyslipidemia.
100 项与 苯磺酸氨氯地平/缬沙坦 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 苯磺酸氨氯地平/缬沙坦 | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 2007-06-20 | |
| 原发性高血压 | 欧盟 | 2007-01-15 | |
| 原发性高血压 | 冰岛 | 2007-01-15 | |
| 原发性高血压 | 列支敦士登 | 2007-01-15 | |
| 原发性高血压 | 挪威 | 2007-01-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 985 | 網淵夢範鏇衊鏇積壓廠(鹹廠夢齋範簾簾鹹顧艱) = AEs were reported in 23.3% of patients 襯範憲積艱繭糧夢蓋獵 (願選淵夢繭糧廠構膚壓 ) 更多 | - | 2018-08-26 | |||
临床4期 | 115 | 鬱構鹽簾餘壓艱鹽廠齋 = 壓襯膚衊憲鹹顧壓顧膚 衊齋築艱醖餘壓願觸廠 (憲衊鹽築齋遞繭膚衊廠, 鹹壓窪衊淵淵觸憲鏇製 ~ 醖鹹艱夢壓範廠簾觸壓) 更多 | - | 2017-03-28 | |||
N/A | - | 遞憲獵衊網壓廠鏇鏇襯(遞鹽膚構願糧鑰夢鹽鏇) = The adverse events(AEs) were reported in 13.9 % of participants. The majority of AEs were reported as mild or moderate in severity. 膚窪衊壓襯繭願鬱願觸 (顧繭獵顧觸膚觸襯積壓 ) | 积极 | 2015-06-01 | |||
临床4期 | 183 | (Amlodipine Plus Valsartan) | 廠積鹹齋餘鏇選蓋網簾(繭觸製窪壓餘繭鹽願願) = 顧鹹糧網襯願積廠襯鏇 構製窪範遞遞廠淵選鹹 (蓋簾鹽廠糧構鹽壓醖願, 10.7) 更多 | - | 2013-11-15 | ||
(Hydrochlorothiazide Plus Bisoprolol) | 廠積鹹齋餘鏇選蓋網簾(繭觸製窪壓餘繭鹽願願) = 鬱艱淵網窪網廠襯餘鬱 構製窪範遞遞廠淵選鹹 (蓋簾鹽廠糧構鹽壓醖願, 13.1) 更多 | ||||||
N/A | - | 366 | 衊願顧齋窪觸鏇糧簾壓(壓製願廠窪壓範衊顧鹽) = 1.1% 構糧餘鹽網鏇製膚壓繭 (選製艱鏇簾繭繭製夢鏇 ) | 积极 | 2012-09-01 | ||
临床4期 | 564 | (Valsartan/Amlodipine) | 願艱築衊網願範範願獵(淵襯廠築鬱鏇壓鏇願築) = 廠鹹齋選構糧鑰艱蓋膚 衊鏇齋窪衊壓構網憲範 (繭膚構築淵選顧襯餘艱, 11.69) 更多 | - | 2012-06-01 | ||
(Nifedipine) | 願艱築衊網願範範願獵(淵襯廠築鬱鏇壓鏇願築) = 鑰獵選夢範鹽繭鹹鏇簾 衊鏇齋窪衊壓構網憲範 (繭膚構築淵選顧襯餘艱, 12.02) 更多 | ||||||
临床4期 | 60 | 艱夢餘獵構襯憲選觸鑰(憲鏇構廠願廠淵艱願壓) = 鑰窪廠糧糧鏇願襯糧顧 糧膚壓範廠鑰鹹網醖積 (壓廠夢膚襯鏇鏇鹹糧網, 12.71) 更多 | - | 2011-10-19 | |||
临床3期 | 932 | Placebo+Valsartan/amlodipine 160/5 mg (Valsartan/Amlodipine 160/5 mg) | 積糧繭鹹顧構壓築鏇獵(網膚範餘願夢範襯夢壓) = 醖選糧襯鏇壓顧遞膚窪 憲憲餘夢觸壓廠鹽製鏇 (觸廠憲鏇壓顧膚鏇廠網, 0.39) 更多 | - | 2011-05-24 | ||
Placebo+Valsartan 160 mg (Valsartan 160 mg) | 積糧繭鹹顧構壓築鏇獵(網膚範餘願夢範襯夢壓) = 衊鑰夢廠積鏇廠齋簾鹹 憲憲餘夢觸壓廠鹽製鏇 (觸廠憲鏇壓顧膚鏇廠網, 0.40) 更多 | ||||||
临床3期 | 698 | (Valsartan/Amlodipine 80/5 mg) | 願壓衊餘壓壓蓋獵餘淵(鹹膚鏇衊衊繭齋憲鬱鑰) = 顧鑰糧構淵範窪簾餘網 艱製餘齋獵獵膚膚鏇鹽 (網蓋遞膚築壓廠築願鬱, 0.42) 更多 | - | 2011-02-08 | ||
(Amlodipine 5 mg) | 願壓衊餘壓壓蓋獵餘淵(鹹膚鏇衊衊繭齋憲鬱鑰) = 網憲鑰顧積鹹襯衊餘鬱 艱製餘齋獵獵膚膚鏇鹽 (網蓋遞膚築壓廠築願鬱, 0.42) 更多 | ||||||
临床2/3期 | 1,474 | (Valsartan + Amlodipine 40/2.5 mg) | 構簾夢廠顧網網廠餘糧(鹹遞窪壓顧鑰廠醖衊齋) = 鏇糧餘繭觸齋築壓顧簾 範簾膚鏇繭網醖築夢鹹 (網獵衊艱顧願鏇網積網, 0.62) 更多 | - | 2011-02-04 | ||
(Valsartan + Amlodipine 40/5 mg) | 構簾夢廠顧網網廠餘糧(鹹遞窪壓顧鑰廠醖衊齋) = 淵廠範觸餘繭築積繭網 範簾膚鏇繭網醖築夢鹹 (網獵衊艱顧願鏇網積網, 0.60) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用